By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 DNA Way

South San Francisco  California  94080-4990  U.S.A.
Phone: 650-225-1000 Fax: 650-225-6000

Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:

Connect with us via Social Media:




Key Statistics

Ownership: Subsidiary

Web Site: Genentech
Employees: 10,000+
Symbol: RHHBY



Company News
Genentech (RHHBY) Release: Updated Data Showed Cotellic In Combination With Zelboraf Helped People With A Specific Type Of Advanced Melanoma Live Significantly Longer Than With Zelboraf Alone 11/23/2015 9:57:33 AM
California Life Sciences Association Adds Leaders From Genentech (RHHBY), Sanford Burnham Prebys Medical Discovery Institute And OncoCyte Corporation To Board Of Directors 11/23/2015 8:19:38 AM
Ophthotech Corporation (OPHT) Announces That Genentech (RHHBY), A Roche (RHHBY) Wholly-Owned Subsidiary, Elects To Exercise Its Right To Opt-In To The Novartis Portion Of The Ophthotech / Novartis AG (NVS) Ex-US Agreement For Fovista® To Treat Wet Age-Related Macular Degeneration 11/17/2015 12:11:04 PM
Genentech (RHHBY) Partners Up with Novartis AG (NVS) on Ex-U.S. Rights to Wet AMD Candidate Fovista 11/17/2015 6:07:36 AM
FDA Green Lights Exelixis (EXEL)-Genentech (RHHBY)'s Vemurafenib/Cobimetinib Combo for Melanoma 11/10/2015 9:59:38 AM
Genentech (RHHBY) Named Founding Partner For Pulmonary Fibrosis Foundation Patient Registry Program 11/5/2015 11:20:59 AM
Xenon Pharmaceuticals Inc. Announces Its Partner Genentech (RHHBY) Has Advanced GDC-0310, A Second Nav1.7 Inhibitor For Pain, Into Clinical Development 10/22/2015 7:27:37 AM
Nimbus Therapeutics Scores a Global License Agreement with Genentech (RHHBY), Financial Terms Undisclosed 10/20/2015 6:16:12 AM
Genentech (RHHBY)’s Ocrelizumab First Investigational Medicine To Show Positive Pivotal Study Results In Both Relapsing And Primary Progressive Forms Of Multiple Sclerosis 10/8/2015 10:02:57 AM
Exelixis (EXEL), Genentech (RHHBY)'s Cobimetinib Succeeds in Pivotal Phase III Trial 10/6/2015 6:08:52 AM